Crezyme325 mg

Crezyme 325 mg is employed for the treatment of patients with Chronic pancreatitis Cystic fibrosis/Mucoviscidosis Following partial or complete pancreatectomy Total gastrectomy Steatorrhea Somatostatinoma Celiac disease and Other conditions associated with pancreatic insufficiency

Each enteric film-coated tablet contains 325 mg of Crezyme 325 mg BP that provides not less than the following enzymatic activity- Amylase 7800 units Protease 455 units Lipase 6500 units

Digestive Enzyme

Crezyme 325 mg is a preparation of Crezyme 325 mg having protease, lipase and amylase enzyme activity. Crezyme 325 mg hydrolyses fats to glycerol and fatty acids, changes protein into proteoses and derived substances and converts starch into dextrins and sugars. Crezyme 325 mg is employed in the conditions where the secretion of pancreatic juice is defcient.

1-3 tablets daily with meal or as per direction of the physician.

2-3 tablets to be swallowed whole with little water immediately after or during meal. Or as directed by the physician

Alkaline media will rupture the enteric coating. As such to prevent bursting out of the content in the stomach Crezyme 325 mg should not be used concurrently with antacid.

Crezyme 325 mg is contraindicated in patients with known hypersensitivity to the drug.

The most frequent side effects are gastrointestinal including nausea, vomiting and abdominal discomfort. Buccal and perianal soreness may occur, particularly in infants. Hypersensitivity reactions manifested by sneezing, lacrimation or skin rashes have been reported.

Pregnancy category C. Not known whether Crezyme 325 mg is distributed into milk. Caution advised if Crezyme 325 mg is used.

Patients known to be allergic to animal protein should be treated with caution.

Excessive dosage may produce a laxative effect. Systemic toxicity does not occur. Very high dosage may cause hyperuricaemia and hyperuricosuria

Keep all medicines out of reach of children. Store in a cool and dry place, protected from light.

Digestive Enzyme

Crezyme 325 mg is a preparation of Crezyme 325 mg, an extract from mammalian pancreas containing enzymes with Amylase, Protease and Lipase activity. It is designed to disintegrate in the alkaline medium of the duodenum where it releases the active enzyme components of Crezyme 325 mg (Amylase, Protease and Lipase). Amylase hydrolyzes dietary starch to yield maltose, maltoriose and a-dextrin. Protease cleaves peptide bonds in the center of proteins and polypeptides and forms amino acids and oligopeptides. Lipase hydrolyzes dietary triglycerides forming two molecules of fatty acid and a molecule of beta-monoglyceride. It converts not less than 25 times its weight of starch into soluble carbohydrates and not less than 25 times its weight of casein into proteoses within 5 mins, (equivalent to 150 times in 30 mins).

Crezyme 325 mg should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Crezyme 325 mg is administered to a nursing mother.